Retatrutide Triple Agonist Enters Phase 3 Trials Targeting Obesity, Sleep Apnea, and Arthritis
The TRIUMPH program tests retatrutide across 5,800+ patients using a novel basket trial design to simultaneously tackle obesity and its complications.
Summary
Retatrutide, a first-in-class triple agonist targeting GIP, GLP-1, and glucagon receptors, enters four Phase 3 trials under the TRIUMPH program. After Phase 2 data showed up to 24% average weight loss over 48 weeks, Eli Lilly is now evaluating whether those gains translate into meaningful improvements in obstructive sleep apnea and knee osteoarthritis. Across 5,800+ participants, the program uses both conventional trials and a novel basket design that nests OSA and OA substudies within the main weight management trials. Primary endpoints include percent body weight change, Apnea-Hypopnea Index shift, and WOMAC knee pain scores. Results could reshape how obesity-related complications are treated medically.
Detailed Summary
Obesity drives a cascade of interconnected conditions — obstructive sleep apnea (OSA), knee osteoarthritis (OA), type 2 diabetes, and cardiovascular disease — yet most drug development programs study these complications in isolation. The TRIUMPH program breaks from that tradition by deploying a basket trial architecture that simultaneously evaluates retatrutide's efficacy across obesity and two of its most prevalent complications in a single integrated development effort. This design is scientifically motivated by the observation that many patients with obesity carry all three burdens concurrently, making separate sequential trials both inefficient and ethically suboptimal.
Retatrutide is a synthetic once-weekly subcutaneous peptide that co-activates three receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This triagonism is intended to synergize appetite suppression, energy expenditure enhancement, and glycemic control beyond what dual agonists like tirzepatide achieve. Phase 2 results were striking — mean weight reductions reached up to 24.2% from baseline over 48 weeks in adults with obesity — a magnitude that substantially exceeds semaglutide (~15%) and approaches bariatric surgery outcomes. The TRIUMPH program is designed to determine whether these reductions are durable and whether they translate into clinically meaningful benefits for OSA and OA.
The TRIUMPH program comprises four multicenter, randomized, double-blind, placebo-controlled Phase 3 trials enrolling over 5,800 participants total. TRIUMPH-1 (NCT05929066, n=2,300) targets adults with BMI ≥27 kg/m² without T2D and includes nested OA (n=560) and OSA (n=240) basket substudies. TRIUMPH-2 (NCT05929079, n=1,120) enrolls adults with T2D and includes an OSA basket (n=440). TRIUMPH-3 (NCT05882045, n=1,950) focuses on Class II/III obesity (BMI ≥35 kg/m²) with established cardiovascular disease. TRIUMPH-4 (NCT05931367, n=435) is a standalone knee OA trial in adults without T2D. Trials 1–3 run 80 weeks of treatment; TRIUMPH-4 runs 68 weeks. All include a 4-week post-treatment safety follow-up.
The primary weight management endpoint across trials is percent change in body weight from baseline to Week 80 (Week 68 in TRIUMPH-4). The OSA primary endpoint is change in Apnea-Hypopnea Index (AHI, events/hour), and the knee OA primary endpoint is change in the WOMAC pain subscale score. The basket trial design controls Type I error at α=0.05, split between the overarching weight management study and each nested basket. Randomization in TRIUMPH-1 and -2 includes three retatrutide dose arms (4 mg, 9 mg, 12 mg QW) plus placebo (1:1:1:1); TRIUMPH-3 and -4 test 9 mg and 12 mg only. Stratification factors include diabetes status, sex, baseline pain severity, and background medications.
Key secondary endpoints include the proportions of participants achieving ≥5%, ≥10%, ≥15%, ≥20%, ≥25%, ≥30%, and even ≥35% weight loss — thresholds that reflect the ambition of the program. Notably, TRIUMPH-1 is the only trial powered to assess ≥35% weight loss response rates, reflecting the expectation that the highest retatrutide doses in non-diabetic patients may approach bariatric-level outcomes. The trials also collect cardiometabolic markers, quality-of-life measures, imaging endpoints (DXA substudy in TRIUMPH-3), and long-term safety data. OSA and OA are increasingly recognized as mechanistically linked to adiposity and cardiovascular risk, and TRIUMPH's nested design allows these connections to be studied without the dilution of statistical power that would occur in a purely standalone approach.
Key Findings
- Phase 2 trials showed retatrutide produced mean weight loss up to 24.2% over 48 weeks — exceeding semaglutide and approaching bariatric surgery outcomes
- TRIUMPH enrolls over 5,800 participants across 4 Phase 3 trials, making it one of the largest obesity drug development programs to date
- Novel basket trial design nests OSA (n=680 across TRIUMPH-1 and -2) and OA substudies (n=560 in TRIUMPH-1, plus n=435 standalone in TRIUMPH-4) within main weight management trials
- Three retatrutide doses tested (4 mg, 9 mg, 12 mg QW) in TRIUMPH-1 and -2; 9 mg and 12 mg in TRIUMPH-3 and -4, all versus placebo
- Primary OSA endpoint is AHI change; primary OA endpoint is WOMAC pain subscale change — both measured at Week 80 (Week 68 for TRIUMPH-4)
- TRIUMPH-1 is uniquely powered to assess ≥35% weight loss response rates, a threshold never before targeted in a registrational obesity trial
- Type I error controlled at α=0.05 split between weight management and each basket indication, enabling independent regulatory evaluation of obesity, OSA, and OA claims
Methodology
Four Phase 3, multicenter, randomized, double-blind, placebo-controlled trials totaling >5,800 participants across distinct populations (non-diabetic obesity, T2D with obesity, high-CVD-risk obesity, knee OA). Retatrutide is administered subcutaneously once weekly at 4 mg, 9 mg, or 12 mg depending on the trial arm. The basket design uses statistical hierarchy with α=0.05 split between overarching weight management and nested disease-specific substudies. Treatment periods run 68–80 weeks with a 4-week safety follow-up.
Study Limitations
This paper describes trial design and rationale rather than results, so no efficacy or safety outcomes are yet available. Weight loss seen in Phase 2 may not fully replicate in Phase 3 populations who have complicating comorbidities such as OSA and OA, as observed with other GLP-1-based agents. The study is fully funded and designed by Eli Lilly, and all authors with academic affiliations are members of the Steering Committee, representing a meaningful conflict of interest that could influence endpoint selection and interpretation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.